腔内灌注治疗恶性胸腔积液的研究现状  

Research Status of Intracavitary Perfusion in the Treatment of Malignant Pleural Effusion

作　　者：雷希君 罗利琼[1] LEI Xi-jun;LUO Li-qiong(Department of Oncology,Tianyou Hospital,Wuhan University of Science and Technology,Wuhan 430064,Hubei,China)

机构地区：[1]武汉科技大学附属天佑医院肿瘤科,湖北武汉430064

出　　处：《医学信息》2024年第3期184-188,共5页Journal of Medical Information

摘　　要：恶性胸腔积液(MPE)是恶性肿瘤常见的相关并发症,一旦出现就提示病情进入了恶化阶段,临床治疗存在非常大的困难,因常可伴随引起胸痛胸闷、喘气等多种症状,耐受力明显下降,严重影响患者的生存质量及预后。目前,胸腔内直接局部灌注抗肿瘤药物的治疗方法应用较为广泛。本文从胸膜硬化剂、热疗、化疗药物、生物免疫抑制剂、中药制剂、抗血管生成剂及载药囊泡等方面入手,分析各类药物的特点及临床应用,以期为未来MPE的研究及治疗提供一定的参考依据。Malignant pleural effusion(MPE)is a common complication of malignant tumors.Once it occurs,it indicates that the condition has entered a stage of deterioration.There are great difficulties in clinical treatment.Because it can often be accompanied by chest pain,chest tightness,wheezing and other symptoms,the tolerance is significantly reduced,which seriously affects the quality of life and prognosis of patients.At present,the treatment of intrapleural direct local perfusion of antitumor drugs is widely used.In this paper,the characteristics and clinical application of various drugs are analyzed from the aspects of pleural sclerosing agent,hyperthermia,chemotherapeutic drugs,biological immunosuppressive agents,traditional Chinese medicine preparations,anti-angiogenic agents and drug-loaded vesicles,in order to provide some reference for the future research and treatment of MPE.

关 键 词：灌注治疗 恶性胸腔积液 囊泡 热疗 恩度 

分 类 号：R734.3[医药卫生—肿瘤]